

Vinay K Rathi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7067821/publications.pdf>

Version: 2024-02-01

71
papers

810
citations

687363

13
h-index

580821

25
g-index

71
all docs

71
docs citations

71
times ranked

974
citing authors

#	ARTICLE	IF	CITATIONS
1	Sharing of clinical trial data among trialists: a cross sectional survey. <i>BMJ, The</i> , 2012, 345, e7570-e7570.	6.0	112
2	Characteristics of Clinical Studies Conducted Over the Total Product Life Cycle of High-Risk Therapeutic Medical Devices Receiving FDA Premarket Approval in 2010 and 2011. <i>JAMA - Journal of the American Medical Association</i> , 2015, 314, 604.	7.4	87
3	Industry Ties in Otolaryngology. <i>Otolaryngology - Head and Neck Surgery</i> , 2015, 152, 993-999.	1.9	70
4	First-Year Report Cards From the Merit-Based Incentive Payment System (MIPS). <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1157.	7.4	36
5	Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 184.	7.4	32
6	How do Orthopaedic Devices Change After Their Initial FDA Premarket Approval?. <i>Clinical Orthopaedics and Related Research</i> , 2016, 474, 1053-1068.	1.5	26
7	Risk factors for thirty-day readmission following flap reconstruction of oncologic defects of the head and neck. <i>Laryngoscope</i> , 2018, 128, 343-349.	2.0	23
8	Modernizing the FDA's 510(k) Pathway. <i>New England Journal of Medicine</i> , 2019, 381, 1891-1893.	27.0	23
9	Assessment of Gender Differences in Clinical Productivity and Medicare Payments Among Otolaryngologists in 2017. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 822.	2.2	21
10	Early experience with the FDA's Breakthrough Devices program. <i>Nature Biotechnology</i> , 2020, 38, 933-938.	17.5	20
11	Patient Preferences in Subglottic Stenosis Treatment: A Discrete Choice Experiment. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 158, 520-526.	1.9	17
12	Analysis of Price Transparency for Oncologic Surgery Among National Cancer Institute "Designated Cancer Centers in 2020. <i>JAMA Surgery</i> , 2021, 156, 582.	4.3	16
13	Telemedicine Services Provided to Medicare Beneficiaries by Otolaryngologists Between 2010 and 2018. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , 2020, 146, 816.	2.2	15
14	Clinical Evidence Supporting US Food and Drug Administration Clearance of Novel Therapeutic Devices via the De Novo Pathway Between 2011 and 2019. <i>JAMA Internal Medicine</i> , 2020, 180, 1701.	5.1	15
15	Trends in Ambulatory Surgery Center Utilization for Otolaryngologic Procedures among Medicare Beneficiaries, 2010-2017. <i>Otolaryngology - Head and Neck Surgery</i> , 2020, 162, 873-880.	1.9	15
16	Payer-Negotiated Prices for Telemedicine Services. <i>Journal of General Internal Medicine</i> , 2022, 37, 3495-3497.	2.6	14
17	The role of industry influence in sinus balloon dilation: Trends over time. <i>Laryngoscope</i> , 2018, 128, 1540-1545.	2.0	13
18	The Merit-Based Incentive Payment System (MIPS): A Primer for Otolaryngologists. <i>Otolaryngology - Head and Neck Surgery</i> , 2018, 159, 410-413.	1.9	13

#	ARTICLE	IF	CITATIONS
19	Hospital-Administered Cancer Therapy Prices for Patients With Private Health Insurance. JAMA Internal Medicine, 2022, 182, 603.	5.1	13
20	What Do Patients Want from Otolaryngologists? A Discrete Choice Experiment. Otolaryngology - Head and Neck Surgery, 2017, 157, 618-624.	1.9	12
21	Getting More Savings from ACOs â€” Can the Pace Be Pushed?. New England Journal of Medicine, 2019, 380, 2190-2192.	27.0	12
22	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2017. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 639.	2.2	11
23	Using Machine Learning to Predict Operating Room Case Duration: A Case Study in Otolaryngology. Otolaryngology - Head and Neck Surgery, 2023, 168, 241-247.	1.9	11
24	Postmarket Modifications of High-Risk Therapeutic Devices in Otolaryngology Cleared by the US Food and Drug Administration. Otolaryngology - Head and Neck Surgery, 2015, 153, 400-408.	1.9	10
25	Bundled Payments in Otolaryngology: Early Lessons from Arkansas. Otolaryngology - Head and Neck Surgery, 2018, 159, 945-947.	1.9	10
26	Private Payerâ€™ Negotiated Prices for Outpatient Otolaryngologic Surgery. Otolaryngology - Head and Neck Surgery, 2022, 167, 262-265.	1.9	10
27	The US Food and Drug Administration 515 Program Initiative. JAMA Cardiology, 2016, 1, 117.	6.1	9
28	Medicareâ€™s New Device-Coverage Pathway â€” Breakthrough or Breakdown?. New England Journal of Medicine, 2021, 384, e43.	27.0	9
29	Industry Sponsorship of Research in Otolaryngology. JAMA Otolaryngology - Head and Neck Surgery, 2017, 143, 842.	2.2	8
30	Regulation of Over-the-Counter Hearing Aids â€” Deafening Silence from the FDA. New England Journal of Medicine, 2020, 383, 1997-2000.	27.0	8
31	US Food and Drug Administration Clearance of Moderate-Risk Otolaryngologic Devices via the 510(k) Process, 1997-2016. Otolaryngology - Head and Neck Surgery, 2017, 157, 608-617.	1.9	7
32	Use of Corticosteroid-Eluting Sinus Stents Between 2012 and 2017. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 90.	2.2	7
33	Female Authorship of Opinion Pieces in Leading Otolaryngology Journals between 2013 and 2018. Otolaryngology - Head and Neck Surgery, 2020, 162, 35-37.	1.9	7
34	Postmarket Clinical Evidence for High-Risk Therapeutic Medical Devices Receiving Food and Drug Administration Premarket Approval in 2010 and 2011. JAMA Network Open, 2020, 3, e2014496.	5.9	7
35	Pneumonia, urinary tract infection, bacteremia, and Clostridioides difficile infection following major head and neck free and pedicled flap surgeries. Oral Oncology, 2021, 122, 105541.	1.5	7
36	Implications of Private Equity Acquisition of Otolaryngology Physician Practices. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 97.	2.2	6

#	ARTICLE	IF	CITATIONS
37	Private payer negotiated prices for FDA approved biologic treatments for allergic diseases. International Forum of Allergy and Rhinology, 2022, 12, 798-801.	2.8	6
38	Out-of-pocket costs of biologic treatments for chronic rhinosinusitis with nasal polyposis in the Medicare population. International Forum of Allergy and Rhinology, 2022, 12, 1295-1298.	2.8	6
39	Publication of Clinical Studies Supporting FDA Premarket Approval for High-Risk Cardiovascular Devices Between 2011 and 2013. JAMA Internal Medicine, 2016, 176, 551.	5.1	5
40	Clinical Evidence Supporting US Food and Drug Administration Premarket Approval of High-Risk Otolaryngologic Devices, 2000-2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 285-288.	1.9	5
41	Educational utility of an online video-based teaching tool for sinus and skull base surgery. Laryngoscope Investigative Otolaryngology, 2021, 6, 195-199.	1.5	4
42	Assessment of FDA Approval for New High-risk Therapeutic Devices Not Meeting Pivotal Study Primary End Points, 2016-2020. JAMA Internal Medicine, 2021, 181, 1409.	5.1	4
43	Off-label Treatment in Otolaryngology—A Cautionary Tale. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 399.	2.2	3
44	CMS Adoption of Prior Authorization Requirements—Implications for Facial Plastic Surgery. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 397.	2.2	3
45	CARES Act Provider Relief Fund Aid to Otolaryngologists in Small Practices. Otolaryngology - Head and Neck Surgery, 2021, 164, 542-544.	1.9	3
46	Graduate Medical Education in Otolaryngology: Making Dollars and Sense of Reform. Otolaryngology - Head and Neck Surgery, 2021, 165, 762-764.	1.9	3
47	Contemporary Incremental Healthcare Costs for Allergic Rhinitis in the United States. Laryngoscope, 2022, 132, 1510-1514.	2.0	3
48	Compensation Rates for Otolaryngologic Procedures Under the Medicare Physician Fee Schedule in 2018. Laryngoscope, 2021, 131, E1785-E1791.	2.0	3
49	Variation in the Price of Head and Neck Surgical Oncology Procedures. Otolaryngology - Head and Neck Surgery, 2023, 168, 536-539.	1.9	3
50	Clinical Evidence Supporting US Food and Drug Administration Approval of Otolaryngologic Prescription Drug Indications, 2005–2014. Otolaryngology - Head and Neck Surgery, 2017, 156, 683-692.	1.9	2
51	Device Safety. Otolaryngologic Clinics of North America, 2019, 52, 103-114.	1.1	2
52	Price Transparency for COVID-19 Testing Among Top US Hospitals. Journal of General Internal Medicine, 2021, 36, 245-247.	2.6	2
53	Physician Performance in the Medicare Merit-based Incentive Payment System. JAMA - Journal of the American Medical Association, 2021, 325, 308.	7.4	2
54	Medicare Reform of Hospital Payment for Inpatient Facial Plastic Procedures. Facial Plastic Surgery and Aesthetic Medicine, 2021, 23, 2-4.	0.9	2

#	ARTICLE	IF	CITATIONS
55	Analyzing Charge Data Systematically Overestimates Health Care Costs. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 921.	2.2	2
56	Preserving and Promoting Competition in the Post-Coronavirus Disease 2019 Healthcare Delivery System. JAMA Health Forum, 2020, 1, e201191.	2.2	2
57	Incremental Revisions across the Life Span of Ophthalmic Devices after Initial Food and Drug Administration Premarket Approval, 1979-2015. Ophthalmology, 2017, 124, 1237-1246.	5.2	2
58	Medical Device User Fee Reauthorization - Back to Basics or Looking Ahead?. New England Journal of Medicine, 2022, 387, 196-199.	27.0	2
59	Commentary: Diagnostic devices in clinical trials have high stakes for patient care. BMJ, The, 2016, 354, i5197.	6.0	1
60	The Centers for Medicare & Medicaid Services' Overhaul of Office-Visit Payments - What's the Bottom Line for Otolaryngology?. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 303.	2.2	1
61	National Geographical Variation in Sinus Balloon Dilation. Otolaryngology - Head and Neck Surgery, 2020, 162, 761-766.	1.9	1
62	Moving Toward Equitable Telemedicine in Otolaryngology - Head and Neck Surgery - Reply. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 220.	2.2	1
63	Otolaryngologist Performance in the Merit-Based Incentive Payment System in 2018. Otolaryngology - Head and Neck Surgery, 2021, , 019459982110328.	1.9	1
64	Surprise Billing in Health Care. JAMA - Journal of the American Medical Association, 2021, 326, 569.	7.4	1
65	Defining the Health Utility Value of Medical Management of Chronic Rhinosinusitis: A Prospective Pilot Study. OTO Open, 2022, 6, .	1.4	1
66	Hospital Prices for Pediatric Tympanostomy Tube Placement and Adenotonsillectomy in 2021. Laryngoscope, 0, , .	2.0	1
67	Payer-negotiated pricing of the hypoglossal nerve stimulator. Journal of Clinical Sleep Medicine, 0, , .	2.6	1
68	The Case for Value-Based Pricing of Corticosteroid-Eluting Sinus Stents. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 221.	2.2	0
69	Otolaryngologists Trail Other Specialties in Industry Payments From Dermal Filler Companies. Laryngoscope, 2021, , .	2.0	0
70	Incomplete Picture of Otolaryngologist Performance in the Merit-Based Incentive Payment System - Reply. JAMA Otolaryngology - Head and Neck Surgery, 2020, 146, 1087.	2.2	0
71	Refining Assumptions About Specialty Compensation Rates. JAMA Surgery, 2020, 155, 1085.	4.3	0